ADQ has launched a new healthcare holding company named Arcera that consolidates the Abu Dhabi sovereign wealth fund’s pharmaceutical interests in Switzerland, Turkey and Egypt, making it one of the MENA region’s largest life sciences businesses.

The new company, based in Abu Dhabi, intends to double its revenue over the next five years through international acquisitions and partnerships, ADQ said in a statement on Monday. 

Arcera’s portfolio will consist of 2,000 branded medicines, addressing illnesses in the areas of neurology, gastroenterology, cardiovascular, pain relief, rheumatology and infection. The holding company owns ADQ’s stakes in Switzerland’s Acino International, Turkey’s Birgi Mefar Group and Egypt’s Amoun Pharmaceutical Co.

Abu Dhabi has taken a forward-leaning stance on healthcare investments coming out of the Covid-19 pandemic and today aims to become a regional hub for life sciences — one of the hottest areas of investment that covers everything from genomics and pharmaceuticals to clinical trials and personalized medicine. ADQ, chaired by UAE National Security Advisor Sheikh Tahnoon bin Zayed, is spearheading a number of those efforts under its mandate to be the lead investor driving the UAE’s economic transformation from petro-state to a knowledge-based economy.

The formation of Arcera follows a familiar playbook: In January 2022 ADQ merged its healthcare subsidiaries with Alpha Dhabi’s Pure Health Medical Supplies to create PureHealth, the country’s largest healthcare provider. ADQ is planning to list the new entity, Bloomberg reports, as it did with Purehealth last December. The firm’s $1 billion listing surged 84% on its debut.